Justin Chakma - 12 Nov 2025 Form 4 Insider Report for ARS Pharmaceuticals, Inc. (SPRY)

Reporting relationship: Chief Business Officer
Issuer ticker: SPRY
Reported as of: 12 Nov 2025
Net transaction value: -$1,450,947
SEC form: 4
Accepted by SEC: 14 Nov 2025, 18:42:54 UTC
Prior SEC filing: 03 Jan 2025
Next SEC filing: 05 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Kathleen Scott, Attorney-in-Fact

Key filing fact

Justin Chakma filed Form 4 for ARS Pharmaceuticals, Inc. (SPRY) on 14 Nov 2025.

Key facts

This page summarizes Justin Chakma's Form 4 filing for ARS Pharmaceuticals, Inc. (SPRY).
4 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 14 Nov 2025, 18:42.

Change

Previous filing in this sequence was filed on 03 Jan 2025.
Current net transaction value: -$1,450,947.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001951238 Primary reporting owner

Chakma Justin

Relationship: Chief Business Officer
Address: C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO
Signature: /s/ Kathleen Scott, Attorney-in-Fact
Signature date: 14 Nov 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SPRY transaction

Common Stock

Options Exercise

Transaction value: $25,200
Shares: +30,000
Change %: +22%
Price: $0.8400
Shares after: 166,380
Date: 12 Nov 2025
Ownership: Direct

SPRY transaction

Common Stock

Sale

Transaction value: $267,357
Shares: -30,000
Change %: -18%
Price: $8.91
Shares after: 136,380
Date: 12 Nov 2025
Ownership: Direct
Footnotes: F1

SPRY transaction

Common Stock

Sale

Transaction value: $1,208,790
Shares: -136,380
Change %: -100%
Price: $8.86
Shares after: 0
Date: 12 Nov 2025
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SPRY transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value: $0
Shares: -30,000
Change %: -25%
Price: $0.000000
Shares after: 89,047
Date: 12 Nov 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 30,000
Exercise price: $0.8400
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The weighted average sale price for the transaction reported was $8.9119, and the range of prices was between $8.87 and $8.97. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

Footnote F2

The weighted average sale price for the transaction reported was $8.8634, and the range of prices was between $8.62 and $9.04. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

Footnote F3

Immediately exercisable.